Vera Therapeutics’ Trutakna meets all prespecified endpoints in ORIGIN 3 IgA nephropathy trial

Bitget2026/10/22 14:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vera Therapeutics reported positive final ORIGIN 3 trial results for Trutakna in adults with primary IgA nephropathy.
The treatment met all prespecified efficacy endpoints, slowing kidney function decline and reducing the risk of kidney disease progression versus placebo.
Safety was generally comparable to placebo, with fewer serious adverse events.
Results were presented at ASN Kidney Week 2026 on October 22 and simultaneously published in The New England Journal of Medicine.
A supplemental biologics license application is planned for the fourth quarter of 2026, with potential full FDA approval in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610221005PRIMZONEFULLFEED9850959) on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vera Therapeutics’ Trutakna meets all prespecified endpoints in ORIGIN 3 IgA nephropathy trial

You may also like

Crypto prices